Результаты поиска

From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes.

Multiple myeloma (MM) remains characterized by recurrent relapse and cumulative treatment burden despite major therapeutic advances. This study compared conventional stepwise regimens with CAR-T cell therapy in terms of QoL, toxicity, cost, and ethical considerations within a model-based comparative framework. This comparative pharmacoeconomic modeling analysis was based on published clinical trial data. Kaplan-Meier survival curves were digitized to estimate mean overall survival (OS) and progression-free survival (PFS) using area-under-the-curve integration. Treatment costs were calculated b

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.

Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demonstrated improved response rates and progression-free survival (PFS), comparative overall survival (OS) data remain limited. We performed a systematic review, network meta-analysis (NMA), and reconstructed individual patient data meta-analysis comparing survival outcomes of quadruplet versus triplet regimens in TI-NDMM. This study adhered to Cochrane and PRI

Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development.

The concept of 'equipoise', or the 'uncertainty principle', has been represented as a central ethical principle, and holds that a subject may be enrolled in a randomized controlled trial (RCT) only if there is true uncertainty about which of the trial arms is most likely to benefit the patient. We sought to estimate the frequency with which equipoise conditions were met in industry-sponsored RCTs in rheumatology, to explore the reasons for any deviations from equipoise, to examine the concept of 'design bias', and to consider alternative ethical formulations that might improve subject safety a

Реальная эффективность обслуживания бортезомиба после введения VMP в санитарную миелому: целевое экспериментальное исследование эмуляции.

Bortezomib-melphalan-prednisone (VMP) — установленный вводный режим для сноса трансплантации, недавно диагностированный несколькими миеломами (NDMM), однако оптимальные стратегии после введения остаются неясными. В ходе этого исследования была проведена оценка эффективности обслуживания бортезомибной системы с использованием пробной эмуляции мишеней. Мы сравнили предполагаемую группу поддержки.KMMWP-174 ) с внешней контрольной когортой из многоцентрового реестра. Число пациентов, прошедших курс лечения 9 Циклы VMP, полученные ≥ частичная реакция и без движения 60 днями. Индексом была дата нача

Biocompatibility in hemodialysis: artificial membrane and human blood interactions.

Hemodialysis, a cornerstone therapy for chronic kidney disease, represented a crucial advance in the evolution of artificial organs. While its success is largely due to its efficiency in removing uremic toxins, an equally important challenge is to uphold the primum non nocere principle by minimizing the harmful effects of membrane-blood interactions. This review examines the complex mechanisms and key interactions underlying membrane biocompatibility, including complement activation, inflammation, and coagulation disturbances, paving the way for their clinical implications. We also summarize r

Belantamab mafodotin, lenalidomide, и дексаметазон для пациентов среднего и слабого типа с недавно поставленным диагнозом миэлома.

Резюме фазы 1/2 В исследовании BelaRd (belantamab mafodotin [беламаф], lenalidomide и dexamethasone) была проведена оценка эффективности и безопасности беналафа в сочетании с линалидомидом и дексаметазоном у недееспособных и слабых пациентов, имеющих право на трансплантацию, с недавно поставленным диагнозом множественной миеломы (НДММ). Часть 1 (n = 36) установить рекомендованный бенамаф фазы 2 Доза (RP2D) 1.9 мг/кг каждый 8 недель (срочная последующая деятельность, 39.3 Месяцами). Частично 2, 30 пациенты были случайными 1::1 в группу А (n = 15), где дозирование беналафа осуществлялось на осно

Multiple Myeloma (Part 2) - Update on The Approach to Bone Disease.

The increase in life expectancy of the world population has led to a concomitant increase in the prevalence of multiple myeloma (MM), a disease that usually affects the elderly population. Bone lesions are frequent in patients with this condition, demanding an early approach, from drug treatment, through radiotherapy to orthopedic surgery (prophylactic or therapeutic) with the objective of preventing or delaying the occurrence of fracture, or, when this event has already occurred, treat it through stabilization or replacement (lesions located in the appendicular skeleton) and/or promote stabil

Opportunities for Savings in Risk Arrangements for Oncologic Care.

ImportanceAs the US accelerates adoption of alternative payment through global payment models such as Accountable Care Organizations (ACOs) or Medicare Advantage (MA), high spending for cancer care is a potential target for savings.ObjectiveTo quantify the extent to which ACOs and other risk-bearing organizations operating in a specific geographic area (hospital referral region [HRR]) could achieve savings by steering patients to efficient medical oncology practices.Design, setting, and participantsThis observational study included serial cross-sections of Medicare beneficiaries with cancer fr

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhi

Biology and Diseases of Dogs

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis.

BACKGROUND AND OBJECTIVES: The objective of this study was to determine, at the time of diagnosis, a CSF and MRI profile of intrathecal compartmentalized inflammation predictive of progression independent of relapse activity (PIRA) in early relapsing-remitting multiple sclerosis (RRMS). METHODS: This five-year prospective study included 80 treatment-naïve patients with RRMS enrolled at time of diagnosis. All patients underwent a lumbar puncture, regular neurologic evaluations including an Expanded Disability Status Scale (EDSS) assessment every 6 months, and an annual 3T brain MRI. PIRA was d

The Landscape of COVID-19 in Cancer Patients: Prevalence, Impacts, and Recommendations.

Cancer patients are susceptible groups to COVID-19, and risk-adjusted models show that most cancer patients have a 25-39% mortality risk if infected with COVID-19. The infection rate of SARS-CoV-2 in cancer patients in China was 0.79% (12 of 1524 patients; 95% CI, 0.31.2%). The case fatality rate of COVID-19 in the overall population ranges from 2.3 to 8.0%; among these, the case fatality rate for cancer patients is at 5.6%. In a retrospective cohort study of 28 COVID-19-infected cancer patients, a total of 15 (53.6%) patients had severe outcomes with a mortality rate of 28.6%. In a pooled ana

Воздействие лисий-барбарбарумного полисачарида на активацию патогенных CD4 + T клеток в модели мыши множественного склероза.

JOURNAL/nrgr/04.03/01300535-202606000-00071/ Рис. 1 v/2026-02-11T151048Z/r/image-tiff Multical sclerosis — серьезное аутоиммунное расстройство, которое в основном поддерживается патогенным скоплением CD4 + T подмножеств клеток. Несмотря на успехи в управлении множественным склерозом, крайне необходимо обеспечить более эффективное и безопасное лечение. В настоящем исследовании мы ввели лициум Барбарум гликопептид в модель мыши экспериментальной аутоиммунной энцефаломиэлит- животной модели множественного склероза- и оценили его воздействие на патогенную активацию клеток CD4 + T как в vivo, так и

Stackelberg Evolutionary Games of Cancer Treatment: What Treatment Strategy to Choose if Cancer Can be Stabilized?

We present a game-theoretic model of a polymorphic cancer cell population where the treatment-induced resistance is a quantitative evolving trait. When stabilization of the tumor burden is possible, we expand the model into a Stackelberg evolutionary game, where the physician is the leader and the cancer cells are followers. The physician chooses a treatment dose to maximize an objective function that is a proxy of the patient's quality of life. In response, the cancer cells evolve a resistance level that maximizes their proliferation and survival. Assuming that cancer is in its ecological equ

Преобразование фотоэнергетики в наноматериалах для точной терапостики.

Быстро развивающаяся область тераностистики направлена на интеграцию терапевтических и диагностических функций в единую платформу для точной медицины, позволяющую одновременно лечить и контролировать болезни. Наноматериалы, основанные на преобразовании фотоэнергии, стали разносторонней платформой, использующей уникальные свойства света для активации тераностистики с высокой пространственной и временной точностью. В настоящем обзоре содержится всеобъемлющий обзор последних изменений в области преобразования фотоэнергетики с использованием наноматериалов с уделением особого внимания их применени

Factors influencing further vertebral height loss following percutaneous vertebroplasty in osteoporotic vertebral compression fractures: A 1-year follow-up study.

BackgroundOsteoporotic vertebral compression fractures (OVCFs) contribute to back pain and functional limitations in older individuals, with percutaneous vertebroplasty (PVP) emerging as a minimally invasive treatment. However, further height loss post-PVP prompts investigation into contributing factors.AimTo investigate the factors associated with further height loss following PVP with cement augmentation in OVCF patients.MethodsA total of 200 OVCF patients who underwent successful PVP between January 2021 and December 2022 were included in this study. "Further height loss" during 1 year of f

Association of response endpoints with survival outcomes in multiple myeloma.

Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analyses of the relationship between response and survival. Generally, these studies have demonstrated that improvements in the quality of response across all stages of treatment are associated with better disease control and longer survival. Thus, achievement of maximal response should be strongly consid

Existing and emerging strategies for fertility preservation in female patients with leukemia.

Leukemia, the most common malignancy in childhood, affects individuals from prepubertal girl to women of reproductive age. It originates from immature hematopoietic cells in the bone marrow and disseminates systemically via the blood and lymphatic circulations. Although survival rates have improved substantially, standard treatments, including intensive chemotherapy and hematopoietic stem cell transplantation, often combined with total body irradiation, are highly gonadotoxic. Consequently, a significant proportion of survivors experience long-term endocrine dysfunction and infertility, with f

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) question

Совпадение в полном тексте источника
… For any maintenance ( n = 244) or lenalidomide-only maintenance ( n = 169) vs no maintenance ( n = 137): 99% power to detect minimal clinically important differences in HRQoL scales with two-sided P value of 0.05. …

Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Chronic lymphocytic leukemia is a lymphoproliferative disorder marked by the expansion of monoclonal, mature CD5+CD23+ B cells in peripheral blood, secondary lymphoid tissues, and bone marrow. The disease exhibits significant heterogeneity, with numerous somatic genetic alterations identified in the neoplastic clone, notably mutated TP53 and immunoglobulin heavy chain mutational statuses. Recent studies emphasize the pivotal roles of genetics and patient fragility in treatment decisions. This complexity underscores the need for a personalized approach, tailoring interventions to individual gen